Knowledge Base

How to identify antibody sequences?

20 December 2023
2 min read

Antibody sequences can be identified through various techniques like polymerase chain reaction (PCR), Next-Generation Sequencing (NGS), and the use of bioinformatics tools and software that analyze and interpret these sequences.

An antibody molecule, also known as an immunoglobulin, consists of four polypeptide chainstwo identical heavy chains and two identical light chains. These chains combine to form a "Y"-shaped molecule. Each (light or heavy) chain of an antibody consists of variable (V) and constant (C) regions, and each has a unique sequence of amino acids.

The variable region provides the specificity of the antibody for binding to the antigen and is what differs from one antibody to another. It consists of three complementarity-determining regions (CDRs), also known as hypervariable regions, embedded in a more constant framework (FR) region. The CDRs in each chain are brought together to form the antigen-binding sites, which determines the specificity of each antibody.

The constant region forms the stem of the "Y" and does not vary greatly among different antibodies. It determines the antibody's class or isotype and can bind to different cell receptors or complement proteins, enabling other parts of the immune system to respond to the antigen.

In reference to antibody sequences, you'll often see CDRs and FRs designated by region - FR1, CDR1, FR2, CDR2, FR3, CDR3, and finally FR4. Variability is highest in the CDR3 region, making CDR3 a crucial region for antigen recognition. By comparing these sequences, scientists can identify the antibodies and gain a lot of information about the immune response.

How antibodies are sequenced, particularly the variable regions, is key to understanding the immune response, and to developing vaccines and antibody-based therapeutics.

Mabwell Reveals Regulatory Green Light for Pioneering Nectin-4 Specific Antibody-Drug Conjugate Entering Stage 3 Research Trials
Latest Hotspot
3 min read
Mabwell Reveals Regulatory Green Light for Pioneering Nectin-4 Specific Antibody-Drug Conjugate Entering Stage 3 Research Trials
19 December 2023
Mabwell announced its Phase III trial application for 9MW2821 vs. standard chemo in advanced urothelial carcinoma.
Read →
Deciphering PRMT5 Inhibitors and Keeping Up with Their Recent Developments
Deciphering PRMT5 Inhibitors and Keeping Up with Their Recent Developments
19 December 2023
Due to the important role that arginine methylation plays in the development of cancer, PRMT5 has become a potential target for cancer treatment.
Read →
Hemab Therapeutics has begun dosing the first participant in a Phase 2 trial to evaluate the effectiveness of HMB-001 for Glanzmann's Thrombasthenia
Latest Hotspot
3 min read
Hemab Therapeutics has begun dosing the first participant in a Phase 2 trial to evaluate the effectiveness of HMB-001 for Glanzmann's Thrombasthenia
19 December 2023
Hemab Therapeutics has reported the initial dosing of a participant in a Stage 2 medical trial assessing the efficacy of HMB-001 in addressing Glanzmann's Thrombasthenia.
Read →
How many sequence modifications exist in the protein sequence?
Knowledge Base
2 min read
How many sequence modifications exist in the protein sequence?
19 December 2023
The exact number of protein sequence variants caused by post-translational modifications (PTMs), which alter proteins after synthesis, is unclear.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.